Logo

News

Latest Press Releases


August 4, 2022

AnHeart Therapeutics to Present Poster and Host Investigator Meeting at WCLC 2022 

August 3, 2022

AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

August 1, 2022

AnHeart Therapeutics Appoints Dr. Shuanglian (Lian) Li as Chief Medical Officer (US)

June 6, 2022

AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022

More Press Releases

Latest News Articles


March 21, 2022
MedCity News

Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy

January, 10-12, 2022
Biotech Showcase

Outsmarting Cancer: Next Generation Therapies

December 16, 2021
Bioworld

Anheart Therapeutics raises $61M in series B for precision oncology pipeline

More News Articles

Media Contact

Kimberly Ha
KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

  • About Us
    • Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
    • Contact
  • Pipeline
    • Overview
    • Taletrectinib AB-106
    • AB-218
    • AB-329
  • Publications
  • Clinical Trials
  • News
    • Press Releases
    • In the News
  • Careers
    • Values
    • Job Opportunities
  • Home
  • About Us
    • Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
    • Contact
  • Pipeline
    • Overview
    • Taletrectinib AB-106
    • AB-218
    • AB-329
  • Publications
  • Clinical Trials
  • News
    • Press Releases
    • In the News
  • Careers
    • Values
    • Job Opportunities
Logo

Contact Us

777 Third Avenue, Suite 1704
New York, NY 10017, USA
Tel: +1 212 466 6378

General Information:
info@anhearttherapeutics.com

Business Development:
bd@anhearttherapeutics.com

Twitter LinkedIn

  • Terms of Use
  • Privacy and Cookies Policy
© 2022 AnHeart Therapeutics All rights reserved.
Website Design: Hane Chow, Inc.